Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

CP-464,005

Alternative Names: cp-464,005, cp464,005, cp 464,005
Latest Update: 2024-05-15
Latest Update Note: PubMed Publication

Product Description

Inhaled insulin for Patients With Type 1 Or Type 2 Diabetes (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00527397)

Mechanisms of Action: Unknown

Novel Mechanism: Yes

Modality: N/A

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Type 1 Diabetes

Phase 3: Type 2 Diabetes|Type 1 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
A2171105

P3

Terminated

Type 2 Diabetes|Type 1 Diabetes

2008-07-01

JapicCTI-070448

P3

Terminated

Type 2 Diabetes|Type 1 Diabetes

2008-07-01

2004-001557-29

P4

Terminated

Type 1 Diabetes

2008-05-12

EXACTA

P3

Completed

Type 2 Diabetes

2008-02-19

Recent News Events

Date

Type

Title

05/15/2024

PubMed

 Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension - an observer blinded active-control trial.

05/15/2024

PubMed

 Global scholarly output on orthodontic temporary anchorage devices (TADs): A silver jublee scientometric analysis.

05/15/2024

PubMed

 Periosteal wrapping of the hamstring tendon autograft improves graft healing and prevents tunnel widening after anterior cruciate ligament anatomic reconstruction.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions